Bio Medica Laboratories IPO Day 3: GMP ₹5 (+₹5)

Welcome back to our daily check-in on the Bio Medica Laboratories SME IPO, currently open for subscription on the NSE. It’s Day 3, and the markets are watching closely. As of now, the subscription numbers across all categories remain at zero. This might sound a bit anticlimactic, but let’s dive deeper into what this means and what the Grey Market Premium (GMP) is telling us.

Subscription Status

The most striking aspect of today’s update is the lack of any subscriptions across the board – Retail, Non-Institutional Investors (NII), and Qualified Institutional Buyers (QIB). For a public issue, seeing 0x across all segments on Day 3 is certainly unusual. Typically, by this stage, we’d expect at least some initial interest, especially from retail investors who often jump in early. The absence of any bids could indicate a few things. Perhaps investors are waiting for the final day or the last couple of days to assess the overall sentiment. It could also suggest that the company’s current valuation or business prospects haven’t yet captured widespread attention. For NII and QIB, their participation is usually more strategic and often comes in the later stages, but even a trickle would have been noteworthy. The lot size is 1000 shares, so even a few applications would start showing up.

GMP Update

Now, let’s turn our attention to the Grey Market Premium (GMP). Yesterday, the GMP for Bio Medica Laboratories was at ₹0. Today, it has seen a positive shift and is currently trading at ₹5. This is a welcome development, albeit a modest one. An increase from zero to ₹5 is encouraging, as it suggests a nascent positive sentiment in the unofficial market. This ₹5 GMP, when added to the issue price of ₹132, hints at an expected listing price of ₹137. While a ₹5 premium isn’t a massive jump, it’s certainly better than remaining stagnant. It indicates that there are buyers willing to pay a slight premium over the issue price, even if the demand hasn’t translated into formal subscriptions yet. This could be a sign that the market is beginning to price in some value for the company.

Should You Apply?

This is where it gets interesting, and a balanced perspective is crucial. On one hand, the subscription numbers are a significant concern. Zero subscriptions on Day 3 are not a typical sign of a highly sought-after IPO. Investors often look for robust subscription figures as a primary indicator of demand and potential listing gains. However, the positive movement in the GMP is a counterpoint. It suggests that despite the lack of formal applications, there’s a growing interest in the grey market, which can sometimes be a leading indicator. The IPO period runs until May 25, 2026, so there are still a couple of days for subscriptions to pick up. If you’re considering applying, it’s wise to weigh these conflicting signals. Remember, SEBI advisors always recommend thorough due diligence. You’ll want to look at the company’s financials, future prospects, and the overall market conditions before making a decision. The current GMP suggests a small potential upside, but the lack of subscription data demands caution. It’s a classic case of “wait and watch” for now.

View Full Bio Medica Laboratories IPO Details